Tests SKB264 with pembrolizumab in several solid tumor types
Tests SKB264 with pembrolizumab in adults with selected solid tumors.
Plain-language title generated from the registry record
Registry title: A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
Key facts
- Where
- Barcelona, Madrid, Santiago de Compostela, Sevilla, and Valencia, SpainSee the 8 sites
- Phase
- Phase 2
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainNo longer taking part
- Hospital del MarBarcelona, SpainNo longer taking part
- Hospital Universitari Dexeus Grupo QuironsaludBarcelona, SpainNo longer taking part
- Hospital Universitari Vall d'HebronBarcelona, SpainNo longer taking part
- Hospital Universitario 12 de OctubreMadrid, SpainNo longer taking part
- Complexo Hospitalario Universitario De SantiagoSantiago de Compostela, SpainNo longer taking part
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainNo longer taking part
- Fundación Instituto Valenciano de OncologíaValencia, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
- Trial code
- NCT05642780EU 2022-502654-14-00
- Record updated
- 19 May 2026
- Original description
The main purpose of this study is to see if SKB264 in combination with pembrolizumab is safe and effective in treating selected solid tumors.Read full original descriptionShow less
A multicenter, open-label, phase 2, basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors
The main purpose of this study is to see if SKB264 in combination with pembrolizumab is safe and effective in treating selected solid tumors.
Inclusion: Male and/or females of age 18 years and older who have histologically or cytologically confirmed locally advanced or metastatic cancer or recurrent cancer (Cervical, Urothelial, Ovarian, Prostate or Endometrial cancer).
Exclusion: Subjects who received any chemotherapy, radiotherapy, immunotherapy, or biologic therapy treatment within 4 weeks before the first dose of the study drug; Subjects with hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or active Tuberculosis; Subjects with a history of allogeneic tissue or solid organ transplant; Subjects with active central nervous system tumors or metastases.